drugset

drugset / Trial / NCT01297413

A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke

NCT01297413 ↗

Phase 1/2 Completed 38 enrolled Stemedica Cell Technologies, Inc. Chandler Regional Medical Center at Chandler AZ · collab Mercy Gilbert Medical Center at AZ · collab UCI Medical Center · collab University of California, San Diego · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and tolerability of allogeneic adult mesenchymal bone marrow cells administered intravenously to patients with ischemic stroke.

Timeline

Start: 2011-02
Primary completion: 2017-09
Completion: 2018-11-15

Publications

Levy ML, Crawford JR, Dib N, Verkh L, Tankovich N, Cramer SC. Phase I/II Study of Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Chronic Stroke. Stroke. 2019 Oct;50(10):2835-2841. doi: 10.1161/STROKEAHA.119.026318. Epub 2019 Sep 9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Allogeneic adult mesenchymal bone marrow stem cells	Cell therapy	0.5 cells/kg	Intravenous
Subject	Allogeneic adult mesenchymal bone marrow stem cells	Cell therapy	1 cells/kg	Intravenous
Subject	Allogeneic adult mesenchymal bone marrow stem cells	Cell therapy	1.5 cells/kg	Intravenous

Indications